Britain and America have concluded a major commercial pact that will preserve zero duties on British drug exports going into the American market.
The Terms of the Deal
As part of the deal, the UK has committed to raise funding on pharmaceuticals through the public health system. This pledge secures that duties on these vital products will stay at nothing for a duration of three years.
This agreement is in response to previous threats to significantly raise tariffs on branded drug imports, with potential rates mentioned as high as double the cost.
"This agreement with the UK bolsters the global environment for cutting-edge drugs and establishes much-needed fairness to U.S.–U.K. medicine commerce," a statement noted.
Economic Impact
Medicines constitute one of the the United Kingdom's largest export categories to the America, which is easily the largest buyer for major British pharmaceutical firms.
Export figures show that in the year leading up to September, the UK exported pharmaceutical products valued at £11.1bn to the US. This value made up a significant portion of total UK exports in that period.
"This guarantee safeguards employment, boosts investment and paves the way for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Specific NHS Changes
The deal involves several key commitments from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must refund to the NHS to prevent overspending will be limited at 15%. Previously, repayments were more than twenty percent.
Broader Context
This agreement comes amid a protracted row between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
This friction were intensified by claims that US customers were paying several times more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while major funding commitments have been announced toward US facilities.
The Science Minister acknowledged that the NHS must spend more on drugs, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
